The US Food and Drug Administration (FDA) placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma: KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uBVEpQ
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidiscip...
-
Publication date: Available online 6 January 2018 Source: Current Problems in Diagnostic Radiology Author(s): Mark D. Kovacs, Maximilian...
-
Background Chronic rhinosinusitis (CRS) is a commonly observed sequela after radiation therapy to the paranasal sinuses. The histopatholo...
-
Abstract Purpose Currently, intraoperative ultrasound in brain tumor surgery is a rapidly propagating option in imaging technology. We e...
-
Publication date: Available online 4 November 2017 Source: Current Problems in Diagnostic Radiology Author(s): Elisabeth R. Garwood, Gre...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Publication date: Available online 6 November 2017 Source: Academic Radiology Author(s): Steven J. Esses, Samir S. Taneja, Andrew B. Ros...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου